Head-To-Head Comparison: Aprea Therapeutics (NASDAQ:APRE) vs. Alkermes (NASDAQ:ALKS)

Alkermes (NASDAQ:ALKS) and Aprea Therapeutics (NASDAQ:APRE) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership and analyst recommendations.

Profitability

This table compares Alkermes and Aprea Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alkermes	3.96%	4.15%	2.19%
Aprea Therapeutics	-4,405.59%	-47.60%	-40.97%

Risk and Volatility

Alkermes has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500. Comparatively, Aprea Therapeutics has a beta of 1.54, suggesting that its stock price is 54% more volatile than the S&P 500.

Institutional & Insider Ownership

95.2% of Alkermes shares are owned by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are owned by institutional investors. 4.6% of Alkermes shares are owned by insiders. Comparatively, 10.5% of Aprea Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Alkermes and Aprea Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.48 billion	4.79	$241.66 million	$0.38	110.87
Aprea Therapeutics	N/A	N/A	-$12.60 million	($1.08)	-0.72

Alkermes has higher revenue and earnings than Aprea Therapeutics. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for Alkermes and Aprea Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	1	4	11	2	2.78
Aprea Therapeutics	1	1	3	0	2.40

Alkermes currently has a consensus price target of $54.47, indicating a potential upside of 29.29%. Aprea Therapeutics has a consensus price target of $3.07, indicating a potential upside of 293.16%. Given Aprea Therapeutics’ higher possible upside, analysts plainly believe Aprea Therapeutics is more favorable than Alkermes.

Summary

Alkermes beats Aprea Therapeutics on 11 of the 14 factors compared between the two stocks.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

About Aprea Therapeutics

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.